


## **Supplemental Figures**




**Supplemental Figure 1.** Kaplan-Meier plots showing overall survival (A) and clinical progression-free survival (B) according to *HSD3B1* genotype for patients receiving conventional NSAA with testosterone suppression (HR, hazard ratio; CI, confidence interval).



**Supplemental Figure 2.** Kaplan-Meier plots showing overall survival (A) and clinical progression-free survival (B) according to *HSD3B1* genotype for patients receiving enzalutamide with testosterone suppression (HR, hazard ratio; CI, confidence interval).



**Supplemental Figure 3.** Kaplan-Meier plots showing overall survival (A) and clinical progression-free survival (B) according to *HSD3B1* genotype, comparing 0, 1 and 2 adrenal-permissive (C) alleles, for patients receiving conventional NSAA with testosterone suppression. (C) Hazard ratio and confidence intervals by genotype.



**Supplemental Figure 4.** Kaplan-Meier plots showing overall survival (A) and clinical progression-free survival (B) according to *HSD3B1* genotype, comparing 0, 1 and 2 adrenal-permissive (C) alleles, for patients receiving enzalutamide with testosterone suppression. (C) Hazard ratio and confidence intervals by genotype.